Revumenib Shows Promise for Advanced Acute Myeloid Leukemia - NCI
Por um escritor misterioso
Descrição
In the AUGMENT-101 trial, treatment with revumenib caused complete remission in about one-third of participants, all of whom had many prior treatments. The targeted therapy is part of a new class of drugs known as menin inhibitors.
Clinical Trial Results National Cancer Institute
Drug 'cures' 33% of patients with aggressive leukaemia in early
Juan Manuel Pérez Huacuja Urista posted on LinkedIn
National Cancer Institute (NCI) on LinkedIn: A new type of
Chemo Shortage: 'Paycheck to Paycheck'; Cancer Blood Test Shines
Financial Navigators Reduce the Cost of Cancer Care - NCI
National Cancer Institute (NCI) on LinkedIn: Cancer Grand
Revumenib: a new therapy for AML patients
Clinical Trial Results - Cancer Currents Blog - NCI
Revumenib trial meets complete remission endpoint for acute
Financial Navigators Reduce the Cost of Cancer Care - NCI
de
por adulto (o preço varia de acordo com o tamanho do grupo)
/i.s3.glbimg.com/v1/AUTH_59edd422c0c84a879bd37670ae4f538a/internal_photos/bs/2022/d/D/qfBB33SZC0THmA3rrqKg/d1f01870-6afa-44ba-959d-52732a654a82.jpg)
